4) Exercise barriers. Participants reported time management and fatigue as main exercise barriers. Moreover, they expressed the concern to be judged for their physical appearance and performance when exercising in groups.
INTRODUCTION AND OBJECTIVES:
The aim of this study was to investigate predictors of long-term mortality in patients with positive lymph nodes at radical prostatectomy.
METHODS: Out of 5,997 patients who consecutively underwent radical prostatectomy at our institution in the years 1992-2014, 564 patients with positive lymph nodes and complete data sets were included in this analysis. The mean number of removed lymph nodes was 14.6. The mean follow-up in the surviving patients was 9.9 years. Age (continuous variable), year of surgery (continuous variable), Gleason Score (<8 versus 8-10), local tumor stage (extracapsular disease versus organ confined), PSA level (<10 ng/ml versus higher or neoadjuvant hormonal therapy), lymph node density (number of involved lymph nodes per number of removed lymph nodes; continuous variable, per 10% increase), lymph node count (continuous variable), and the number of positive lymph nodes (continuous variable) were included in the multivariable competing risk analysis with prostate cancer mortality as endpoint.
RESULTS: After 20 years, 28% of patients (95% confidence interval, CI, 20-36%) died of non-prostate cancer (competing) causes, whereas 29% (95% CI 23-36%) died of prostate cancer. Only lymph node density (per 10% increase, hazard ratio, HR, 1.2, 95% CI 1.0-1.3, p[0.0056) and Gleason score (8-10 versus <8: HR 6.1, 95% CI 3.3-11.4, p<0.0001) predicted prostate cancer mortality. Patients with a Gleason score <8 and a lymph node density <median (11%) had a 20-year prostate cancer mortality of only 4% (95% CI 3-5%), whereas this rate in patients with Gleason score 8-10 and a lymph node density >/[median was 42% (32-52%), p<0.0001.
CONCLUSIONS: Mortality in patients with positive lymph nodes is determined by tumor biology, neither the year of surgery nor a more extensive lymph node dissection were associated with outcome. Patients with a lymph node density of <11% and a Gleason score <8 had an excellent long-term outcome.
Source of Funding: None.
PD25-10 ESTIMATION OF THE RISK OF MISSING ADVERSE PATHOLOGICAL PROSTATE CANCER FEATURES AFTER SALVAGE RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR FOCAL SALVAGE THERAPIES
Luca Boeri*, Vidit Sharma, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tollefson, John C. Cheville, R. Jeffrey Karnes, Rochester, MN INTRODUCTION AND OBJECTIVES: Focal salvage therapies (FST) for locally recurrence prostate cancer (PCa) after primary radiotherapy (RT) can reduce the risk of adverse events associated with salvage radical prostatectomy (sRP) while maintaining cancer control, in selected patients. However, the risk of missing adverse PCa features undergoing FST instead of sRP has never been investigated. We aimed to assess the rates and predictors of adverse PCa features in patients eligible for FST who ultimately underwent sRP. METHODS: We reviewed 120 patients with locally recurrent PCa after RT who underwent sRP and extended pelvic lymph node dissection (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Metastatic disease was excluded by choline PET and bone scan. Pre RT PSA, clinical stage (cT), biopsy Gleason score (GS) prior to RT and prior to sRP, PSA nadir, PSA prior to surgery, and pathohistology of sRP specimens were analysed. Eligibility criteria for FST were based on EAU Guidelines: cT1-cT2 PCa, initial GS 7 and pre-salvage PSA <10 ng/mL. Adverse features after sRP were defined as: GS !8, pNþ and seminal vesicle invasion (SVI) at sRP. Descriptive statistics and logistic regression models were used to describe the whole cohort.
RESULTS: Overall, the median (interquartile range) age at sRP was 66.8 (62.1-71.7) years and the median pre sRP PSA was 4.2 (2.2-7.6) ng/mL. 63 (52.5%) patients had a GS 7 and 54 (45%) men had cT1 disease prior to sRP. According to EAU Guidelines, 55 (45.8%) patients were eligible for FST. Among those, 22 (40%) patients had adverse PCa features after sRP. In particular, SVI, pNþ and GS !8 at sRP were found in 12 (21.8%), 9 (16.4%) and 7 (12.7%) men, respectively. In patients with indications for FST, those with adverse PCa features at sRP had higher PSA nadir (0.9 vs. 0.4 ng/mL; p[0.019) and higher rates of GS 4þ3 PCa pre sRP (54.5% vs. 18.2%, p[0.01) than those without adverse PCa features. At univariable logistic regression analysis, pre surgical GS 4þ3 (p[0.003) and higher PSA nadir (p[0.018) were associated with the risk of having adverse features at sRP while age, cT, PSA prior to sRP were not.
CONCLUSIONS: Approximately 40% of patients potentially eligible for FST showed adverse PCa characteristics when submitted to sRP. In particular 22% and 16% of those will have SVI and pNþ disease. A confirmatory GS 4þ3 biopsy for recurrence and higher PSA nadir were associated with the risk of having adverse PCa features at salvage surgery. These results suggest the need for improving the selection of candidates for FST.
Source of Funding: none

PD25-11 MULTIVISCERAL SURGERY IN MEN WITH LOCALLY ADVANCED, SYMPTOMATIC CASTRATION RESISTANT PROSTATE CANCER
Friederike Haidl*, David Pfister, Daniel Porres, Leonidas Karapanos, Johannes Salem, Axel Heidenreich, Cologne, Germany INTRODUCTION AND OBJECTIVES: Local complications such as gross hematuria and clotting, repetitive blood transfusions, upper and lower urinary tract obstruction, intestinal obstruction, and treatmentrefractory pelvic pain represent significant complications of locally advanced CRPC despite the use of life prolonging agents. It is the purpose of our study to retrospectively review the surgical, symptomatic and oncological outcome following palliative, extensive pelvic surgery.
METHODS: 103 patients with locally advanced CRPC underwent palliative pelvic surgery: radical cystoprostatectomy in n[80 (61.5%), radical prostatectomy with continent vesicostomy in n[9 (8.7%) and anterior plus posterior exenteration in n[17 (16.5%). All patients underwent local staging via MRI of the small pelvis, cystoscopy and rectoscopy. Systemic staging was done with CT scans of the chest, abdomen, pelvis and bone scans. Perioperative complications were assessed according to Clavien-Dindo classification and symptom-free (SFS), cancer specific survival (CSS) were evaluated.
RESULTS: Indications for surgery were lower or upper urinary tract obstruction in 56 (54.3%) and 41 (39.8%), resp., hematuria and blood transfusions in 23 (22.3%), rectal infiltration with/without obstructive ileus in 17 (16.5%), refractory pelvic pain in 13 (12.6%). 67 (65.1%) pts had a combination of various symptoms. Clavien-Dindo grade 2, 3 and 4 complications developed in 27 (26.2%), 9 (8.7%) and 6 (5.8%), resp. After a median follow-up of 36.5 (3 e 123) months, the SFS at 1 and 3
